IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: Its correlation with disease activity

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Ye, Liang ^a,b   Ji, Ling ^c   Wen, Zhongyang ^a,b   Zhou, Yanfei ^a,b   Hu, Dongsheng ^a   Li, Yanqun ^a,b   Yu, Ting ^a,b   Chen, Bingni ^a,b   Zhang, Jinshun ^a,b   Ding, Liping ^a,b   Du, Jing ^c   Huang, Zhong ^a,b  

^a Shenzhen University   (China)

^b SHENZHEN UNIVERSITY   (China)

^c PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

Author keywords

Autoimmunity; Cytokines; Interleukin 37; Peripheral blood mononuclear cell; Systemic lupus erythematosus

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 37; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; BLOOD PROTEINS; CASE-CONTROL STUDIES; CYTOKINES; DEMOGRAPHY; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1; KIDNEY; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; YOUNG ADULT;

EID: 84899135757     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-69     Document Type: Article

References (29)

1. Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E, Klunker S, Meyer N, O'Mahony L, Palomares O, Rhyner C, Ouaked N, Schaffartzik A, Van De Veen W, Zeller S, Zimmermann M, Akdis CA. Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases. J Allergy Clin Immunol 2011, 127:701-721. 10.1016/j.jaci.2010.11.050, 21377040.
2. Boraschi D, Lucchesi D, Hainzl S, Leitner M, Maier E, Mangelberger D, Oostingh GJ, Pfaller T, Pixner C, Posselt G, Italiani P, Nold MF, Nold-Petry CA, Bufler P, Dinarello CA. IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw 2011, 22:127-147.
3. Dinarello C, Arend W, Sims J, Smith D, Blumberg H, O'Neill L, Goldbach-Mansky R, Pizarro T, Hoffman H, Bufler P, Nold M, Ghezzi P, Mantovani A, Garlanda C, Boraschi D, Rubartelli A, Netea M, van der Meer J, Joosten L, Mandrup-Poulsen T, Donath M, Lewis E, Pfeilschifter J, Martin M, Kracht M, Muehl H, Novick D, Lukic M, Conti B, Solinger A, Kelk P, van de Veerdonk F, Gabel C. IL-1 family nomenclature. Nat Immunol 2010, 11:973. 10.1038/ni1110-973, 20959797.
4. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010, 11:1014-1022. 10.1038/ni.1944, 3537119, 20935647.
5. Bufler P, Gamboni-Robertson F, Azam T, Kim SH, Dinarello CA. Interleukin-1 homologues IL-1F7b and IL-18 contain functional mRNA instability elements within the coding region responsive to lipopolysaccharide. Biochem J 2004, 381:503-510. 10.1042/BJ20040217, 1133858, 15046617.
6. McNamee EN, Masterson JC, Jedlicka P, McManus M, Grenz A, Collins CB, Nold MF, Nold-Petry C, Bufler P, Dinarello CA, Rivera-Nieves J. Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci U S A 2011, 108:16711-16716. 10.1073/pnas.1111982108, 3189085, 21873195.
7. Sakai N, Van Sweringen HL, Belizaire RM, Quillin RC, Schuster R, Blanchard J, Burns JM, Tevar AD, Edwards MJ, Lentsch AB. Interleukin-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells. J Gastroenterol Hepatol 2012, 27:1609-1616. 10.1111/j.1440-1746.2012.07187.x, 3448792, 22646996.
8. Ballak DB, Suzhao L, Janna AVD, Alexander RM, Henry J, Anneke H, Gert-Jan G, Philip B, Sander K, Leo ABJ, Herbert T, Charles AD, Mihai GN, Cees JT, Rinke S. IL-37 protects against obesity-induced inflammation and insulin resistance. Cytokine 2013, 63:245-246.
9. Imaeda H, Takahashi K, Fujimoto T, Kasumi E, Ban H, Bamba S, Sonoda H, Shimizu T, Fujiyam Y, Andoh A. Epithelial expression of interleukin-37b in inflammatory bowel disease. Clin Exp Immunol 2013, 172:410-416. 10.1111/cei.12061, 23600829.
10. Crispín JC, Liossis S-NC, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, Tsokos GC. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 2010, 16:47-57. 10.1016/j.molmed.2009.12.005, 2823952, 20138006.
11. Jacob N, Stohl W. Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther 2011, 13:228. 10.1186/ar3349, 3239336, 21745419.
12. Su DL, Lu ZM, Shen MN, Li X, Sun LY. Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE. J Biomed Biotechnol 2012, 2012:347141. 3303597, 22500087.
13. Bezalel S, Asher I, Elbirt D, Sthoeger ZM. Novel biological treatments for systemic lupus erythematosus: current and future modalities. Isr Med Assoc J 2012, 14:508-514.
14. Song L, Qiu F, Fan Y, Ding F, Liu H, Shu Q, Liu W, Li X. Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus. J Clin Immunol 2013, 33:111-117. 10.1007/s10875-012-9791-z, 22961070.
15. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification ofsystemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
16. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992, 35:630-640. 10.1002/art.1780350606, 1599520.
17. Wu Q, Yang Q, Lourenco E, Sun H, Zhang Y. Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity. Arthritis Res Ther 2011, 13:R88. 10.1186/ar3363, 3218903, 21679442.
18. Novick D, Elbirt D, Miller G, Dinarello CA, Rubinstein M, Sthoeger ZM. High circulating levels of free interleukin-18 in patients with active SLE in the presence of elevated levels of interleukin-18 binding protein. J Autoimmun 2010, 34:121-126. 10.1016/j.jaut.2009.08.002, 19699611.
19. Yu SL, Kuan WP, Wong CK, Li EK, Tam LS. Immunopathological roles of cytokines, chemokines, signaling molecules, and pattern-recognition receptors in systemic lupus erythematosus. Clin Dev Immunol 2012, 2012:715190. 3270521, 22312407.
20. Apostolidis SA, Lieberman LA, Kis-Toth K, Crispín JC, Tsokos GC. The dysregulation of cytokine networks in systemic lupus erythematosus. J Interferon Cytokines Res 2011, 31:769-779.
21. Tsai C-Y, Wu T-H, Yu C-L, Lu J-Y, Tsai Y-Y. Increased excretions of β2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 2000, 85:207-214. 10.1159/000045663, 10867535.
22. Herrera-Esparza R, Barbosa-Cisneros O, Villalobos-Hurtado R, Avalos-Díaz E. Renal expression of IL-6 and TNFα genes in lupus nephritis. Lupus 1998, 7:154-158. 10.1191/096120398678919949, 9607638.
23. Uppal SS, Hayat SJ, Raghupathy R. Efficacy and safety of infliximab in active SLE: a pilot study. Lupus 2009, 18:690-697. 10.1177/0961203309102557, 19502264.
24. Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 2005, 64:630-633. 10.1136/ard.2004.025858, 1755442, 15345502.
25. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010, 62:542-552. 10.1002/art.27221, 3057537, 20112381.
26. Llorente L, Weiping Z, Yves L, Yvonne RP, John W, Jorge AV, Brigitte MF, Jean CB, Donato AS, Pierre G, Dominique E. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995, 181:839-844. 10.1084/jem.181.3.839, 2191898, 7869046.
27. Wong CK, Wong PTY, Tam LS, Li EK, Chen DP, Lam CWK. Activation profile of intracellular mitogen-activated protein kinases in peripheral lymphocytes of patients with systemic lupus erythematosus. J Clin Immunol 2009, 29:738-746. 10.1007/s10875-009-9318-4, 19756990.
28. Thalhamer T, McGrath MA, Harnett MM. MAPKs and their relevance to arthritis and inflammation. Rheumatology 2008, 47:409-414.
29. Iwata Y, Wada T, Furuichi K, Sakai N, Matsushima K, Yokoyama H, Kobayashi K. p38 Mitogen-activated protein kinase contributes to autoimmune renal injury in MRL-Fas lpr mice. J Am Soc Nephrol 2003, 14:57-67. 10.1097/01.ASN.0000037402.83851.5F, 12506138.